1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Prostate Cancer [2017]

Prostate Cancer [2017]

  • October 2017
  • ID: 5214612
  • Format: PDF
  • By Firstword Pharma


Table of Contents

How will established and emerging agents reshape the prostate cancer treatment landscape?

A multitude of novel therapies have been approved for prostate cancer over the past ten years, but what does the future hold? Key opinion leaders (KOLs) are excited about expanded approvals for hormonal therapies and personalised approaches with PARP inhibitors and PD-1/PD-L1 immunotherapies, but which therapy will stand out in an evolving and competitive landscape? Other innovative targeted agents are also in the pipeline but which segment of the market can they expect to capture?

Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in KOL Insight: Prostate Cancer. Twelve US and European KOLs provide their candid insights on five marketed products and ten Phase III pipeline programmes.

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 6 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top Takeaways
• How will the LATITUDE/STAMPEDE results for Zytiga impact the treatment of prostate cancer? Will Zytiga become the new standard of care in the metastatic hormone-sensitive prostate cancer (mHSPC) space and if so, how will this impact competitor Xtandi?
• Is Xtandi expected to transition up the treatment algorithm? With up to seven Phase III studies investigating Xtandi across numerous settings, find out which studies KOLs are most optimistic about.
• Will next-generation antiandrogens, apalutamide and darolutamide, be able to differentiate themselves in a competitive market? How can the potential new market entrants successfully stand out from established agents?
• Bone-targeted therapies set to play an important role in the future of prostate cancer'Could bone-targeted therapies shift earlier in the treatment algorithm in combination with Zytiga or Xtandi?
• Is the jury still out on immunotherapies in prostate cancer? Do KOLs believe that vaccine-based therapies or PD-1/PD-L1 checkpoint inhibitors hold any opportunity in prostate cancer and if so, which approaches are the most promising?
• Do PARP inhibitors represent an important advance for the personalised treatment of prostate cancer? Find out how KOLs think olaparib (Lynparza) and rucaparib (Rubraca) compare and if they can change treatment for biomarker-selected patient groups?
• Which innovative mechanisms of action are KOLs most excited about? Array BioPharma/Roche’s Akt inhibitor ipatasertib is also in the Phase III pipeline but how do the KOLs view this novel mechanism in prostate cancer?
• How will future treatment pathways evolve for the treatment of prostate cancer? Find out if immune checkpoint inhibitors or PARP inhibitors are expected to play an important role.


“It is very likely that the PARP inhibitors will be approved. Out of all the new agents being tested, the PARP inhibitors are probably the most likely to be successful.”US Key Opinion Leader

“It’s the treatment combinations that will have an impact, much more than the [individual] therapies themselves. What will really change the landscape is not the treatments themselves, but the way we select patients.”EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies
• Xtandi (enzalutamide; Astellas/Medivation)
• Zytiga (abiraterone acetate; J&J)
• Xofigo (radium-223 dichloride; Algeta/Bayer)
• Xgeva/Prolia (denosumab; Amgen)
• Provenge (sipuleucel-T; Sanpower Group)

Pipeline Therapies
• apalutamide (ARN-509; J&J)
• darolutamide (ODM-201; Bayer/Orion)
• PROSTVAC (rilimogene galvacirepvec/ rilimogene glafolivec; Bavarian Nordic/Bristol-Myers Squibb)
• DCVAC/PCa (stapuldencel-T; Sotio)
• ProstAtak (aglatimagene besadenovec; Advantagene)
• Tecentriq (atezolizumab; Roche)
• Keytruda (pembrolizumab; Merck & Co.)
• Lynparza (olaparib; AstraZeneca)
• Rubraca (rucaparib; Clovis Oncology)
• ipatasertib (Array BioPharma/Roche)

KOLs interviewed

KOLs from North America
• Dr. Rahul Aggarwal MD, Developmental Therapeutics Specialist and Genitourinary Oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center, University of California • San Francisco, San Francisco, CA
• Dr. Tomasz M. Beer MD FACP, Professor, Division of Hematology and Medical Oncology and Deputy Director, Oregon Health & Science University Knight Cancer Institute, Portland, OR
• Dr. David E. Crawford MD, Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado, Aurora, CO
• Dr. Saby George MD FACP, Associate Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
• Dr. Neha Vapiwala MD, Associate Professor of Radiation Oncology at the Hospital of the University of Pennsylvania, Philadelphia, PA
• Dr. Michael J. Zelefsky MD, Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY

KOLs from Europe
• Dr. Raffaele Ardito, Head of the Day Oncology Unit at Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
• Dr. Nicolas B Delongchamps MD, Consultant, Cochin Hospital and Professor at Paris Descartes University, Paris, France
• Dr. John P Logue MB, MRCP, FRCR, Consultant Clinical Oncologist, the Christie Hospital, Manchester, UK
• Dr. Chris Parker MD FRCR MRCP, Senior Lecturer and Honorary Consultant in Clinical Oncology and Prostate Cancer Translational Research at The Institute of Cancer Research and The Royal Marsden, London, UK
• Anonymous German KOL, Chief Physician and Professor of Urologic Oncology at a major Hospital, Germany
• Anonymous German KOL, Professor in the Department of Urology at a major University Hospital, Germany

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019" provides an overview ...

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Point-of-Care (POC) Analyzers - Medical Devices Pipeline Assessment, 2019" provides an ...

Toll Like Receptor 3 - Pipeline Review, H1 2020

Toll Like Receptor 3 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Toll Like Receptor 3 - Pipeline Review, H1 2020SummaryToll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on